{
  "id": 20871854,
  "title": "Trisalus director Gary B. Gordon acquires $22,000 in common stock",
  "url": "https://urgent.news/2026/11/20/trisalus-director-gary-b-gordon-acquires-22-000-in-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T08:00:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/trisalus-director-gary-b-gordon-acquires-22000-in-common-stock-93CH-5040888"
  },
  "original_language": "en",
  "account": "TriSalus Life Sciences, Inc. (TLSI) director Gary B. Gordon made a significant move in the market on November 17, 2026, when he purchased 10,000 shares of the company's common stock. This transaction, valued at $22,000, was executed at a price of $2.20 per share. Given the current market conditions, with the stock trading near its 52-week low of $2.17, Gordon's acquisition represents a notable investment in the company. Post-acquisition, Gordon now directly owns a total of 82,510 shares of TriSalus Life Sciences common stock.\n\nAnalysts have taken a closer look at the stock, suggesting it may be undervalued at its current price point. According to InvestingPro, the stock's Fair Value estimate indicates there could be upward potential in its price. The company has also been deemed to have a sound financial health status, as rated FAIR. For those interested in a deeper dive into the company's prospects, a Pro Research Report is available for review.\n\nRecently, TriSalus Life Sciences reported its Q3 earnings, which showed an 11% year-over-year revenue increase to $12.9 million. However, the company fell short of estimates, with the actual revenue coming in below the expected $14.0 million. The company also reported an adjusted EBITDA loss of $4.7 million, exceeding the anticipated $4.2 million loss. Furthermore, TriSalus incurred an adjusted earnings loss of $0.15 per share, which was worse than the expected loss of $0.12 per share. In response to these results, Canaccord adjusted its price target for TriSalus to $4.00, down from the previous $7.00, while maintaining a Buy rating.\n\nThese recent developments highlight the challenges the company is facing in meeting investor expectations, particularly in a market where the stock has been trading at a low level. As investors weigh their options, they may find the additional insights provided by the Pro Research Report particularly useful in making informed decisions about TriSalus Life Sciences.",
  "summary": null,
  "key_points": [
    "Gary B. Gordon buys 10,000 shares at $2.20 each, totaling $22,000",
    "Stock trading near 52-week low of $2.17, Gordon's acquisition notable",
    "Post-acquisition, Gordon owns 82,510 shares of TriSalus Life Sciences"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}